Noble Financial analyst Robert LeBoyer reiterated a Buy rating on Unicycive Therapeutics (UNCY – Research Report) today and set a price ...

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of ...

LOS ALTOS, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive ...

Karnataka: Shilpa Medicare CDMO partner Unicycive Therapeutics, Inc. has announced that the U.S. Food and Drug Administration ...

Unicycive has entered into a long term manufacturing contract with Shilpa Medicare for the supply of the product at commercial scale once approved by the USFDA. With Unicycive's NDA now under review, ...

The FDA has started a review of Unicycive Therapeutics' drug for hyperphosphataemia in patients with chronic kidney disease ...

Unicycive, which is seeking an FDA green light for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease who are on dialysis, Monday said the agency set a target ...

FDA sets PDUFA Action Date of June 28, 2025 ...

PISCATAWAY, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- The Waveform Architecture for Virtualized Ecosystems (WAVE) Consortium is ...

On Friday, Unicycive Therapeutics Inc (UNCY) stock saw a modest uptick, ending the day at $0.59 which represents a slight increase of $0.02 or 3.51% from the prior close of $0.57. The stock opened at ...

UNCY Stock Performance and Moving Averages. In recent trading, Unicycive Therapeutics Inc (UNCY) stock price has shown some volatility, fluctuating 6.50% over the last five trades ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated ...